ICMR and Panacea Biotec conduct third phase trials for indigenous dengue vaccine in India with promising results.

A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

India's DengiAll vaccine trial is nearing completion. ICMR scientists anticipate enrolling 10,500 participants by October ...

The one-shot vaccine, developed by Panacea Biotec and branded as DengiAll, is being tested through a multi-centre, ...

An ongoing Phase III clinical trial of DengiAll, a one-shot dengue vaccine developed by Panacea Biotec, is progressing in ...

The report, which covered the week of June 16-22, revealed that 781 confirmed cases were reported out of 5,943 suspected cases across 20 states and 101 LGAs ...

Donald Trump again has threatened a tariff on imported drugs, but has given the drug makers a year or so "to get their act together".

With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax’s GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique ...

Here, we review the most recent findings on the Crimean–Congo hemorrhagic fever virus molecular biology and pathogenesis, including aspects of virus–host cell interactions.